Who
James A. Schoeneck
Director
Company insider
Files Form 4 as: Director, Calidi Biotherapeutics; Interim President, Kyntra Bio; Director, AnaptysBio; President and CEO, Depomed.
In numbers
- Trades disclosed
- 168
- Buys
- 6
- Sells
- 11
- Bought
- $604K
- Sold
- $2.4M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 10 Dec 2007
- Last trade
- 17 Aug 2026
- Last filed
- 19 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 19 Aug 2026 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 12 Jun 2026filed 17 Jun 2026 | KYNB Kyntra Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 12 Jun 2026filed 17 Jun 2026 | KYNB Kyntra Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 21 Aug 2025filed 25 Aug 2025 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —75,000 | filing |
| 21 Aug 2025filed 25 Aug 2025 | CLDI Calidi BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $150K75,000 at $2.00 | filing |
| 9 Jul 2025filed 15 Jul 2025 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —164,493 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | KYNB Kyntra BioBiotechnology | SEC FORM 4 Bought | $119K23,567 at $5.07 | filing |
| 4 Jun 2025filed 6 Jun 2025 | KYNB Kyntra Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 21 Mar 2025filed 24 Mar 2025 | KYNB Kyntra BioBiotechnology | SEC FORM 4 Bought | $17K50,000 at $0.34 | filing |
| 20 Mar 2025filed 24 Mar 2025 | KYNB Kyntra BioBiotechnology | SEC FORM 4 Bought | $88K250,000 at $0.35 | filing |
| 20 Sep 2024filed 15 Oct 2024 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,217 | filing |
| 28 Jun 2024filed 2 Jul 2024 | CLDI Calidi BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —79,687 | filing |
| 5 Jun 2024filed 6 Jun 2024 | KYNB Kyntra Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 3 Jun 2024filed 5 Jun 2024 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —173,000 | filing |
| 3 Jun 2024filed 5 Jun 2024 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —173,000 | filing |
| 3 Jun 2024filed 5 Jun 2024 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —375,000 | filing |
| 3 Jun 2024filed 5 Jun 2024 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —375,000 | filing |
| 3 Jun 2024filed 5 Jun 2024 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —548,000 | filing |
| 3 Jun 2024filed 5 Jun 2024 | CLDI Calidi BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $35K173,000 at $0.20 | filing |
News
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026CLDI · manilatimes.net · 19 Oct 2026Kyntra Bio (KYNB): Can Its New Strategy And Pipeline Revive Investor Interest?KYNB · rttnews.com · 19 Oct 2026Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Shares Down 0.4% – Here's What HappenedCLDI · tickerreport.com · 17 Oct 2026Kyntra Bio Inc (KYNB) – What Are Brokerages Saying About This Stock?KYNB · dailypolitical.com · 14 Oct 2026Prothena (NASDAQ:PRTA) vs. Kyntra Bio (NASDAQ:KYNB) Financial ReviewKYNB · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name James A. Schoeneck; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.